LEI: 213800FLQUB9J289RU66
19 December 2024
BATM Advanced Communications Limited
("BATM" or "the Group")
Result of AGM and Director Appointment
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that at its Annual General Meeting ("AGM" or the "Meeting"), held earlier today, all resolutions were duly passed, including the resolution appointing Dr. Shmuel (Muli) Ben Zvi as a Non-executive Director of the Group with effect from the conclusion of the Meeting.
Details of the voting results, which should be read alongside the Notice of AGM, are below:
Resolution |
Votes for* |
Votes against |
Votes withheld |
Total votes cast |
||
|
No. of votes |
% of votes cast** |
No. of votes |
% of votes cast** |
No. of votes |
|
1 |
302,686,902 |
99.99 |
37,322 |
0.01 |
119,927 |
302,844,151 |
2 |
289,249,227 |
95.54 |
13,489,997 |
4.46 |
104,927 |
302,844,151 |
3 |
290,229,434 |
99.98 |
67,322 |
0.02 |
12,547,395 |
302,844,151 |
4 |
189,028,376 |
91.79 |
16,916,348 |
8.21 |
104,927 |
206,049,651 |
5 |
298,028,865 |
98.44 |
4,710,359 |
1.56 |
104,927 |
302,844,151 |
6 |
298,028,865 |
98.44 |
4,710,359 |
1.56 |
104,927 |
302,844,151 |
7 |
302,619,454 |
99.99 |
44,770 |
0.01 |
179,927 |
302,844,151 |
8 |
302,219,045 |
99.85 |
445,179 |
0.15 |
179,927 |
302,844,151 |
9 |
298,368,344 |
98.56 |
4,370,880 |
1.44 |
104,927 |
302,844,151 |
10 |
201,573,844 |
66.60 |
101,090,380 |
33.40 |
179,927 |
302,844,151 |
11 |
185,567,384 |
91.49 |
17,255,952 |
8.51 |
3,226,315 |
206,049,651 |
12 |
302,587,954 |
99.94 |
167,895 |
0.06 |
88,302 |
302,844,151 |
13 |
289,994,081 |
95.77 |
12,821,768 |
4.23 |
28,302 |
302,844,151 |
* Includes discretionary votes
**Excludes withheld votes
The Board is pleased that all resolutions were passed by the requisite majority of the shareholders who voted, but notes that over 20% of votes cast were against the Board's recommendation in respect of resolution 10. The Board will engage with shareholders in respect of this resolution to ensure their views are understood. In accordance with provision 4 of the
Other than the below, there are no other required disclosures pursuant to
Current directorships held in public companies |
Directorships in public companies held within the past five years |
Protalix Biotherapeutics Inc |
Bank Leumi Le Israel BM |
|
Sol-Gel Technologies Ltd |
|
VBL Therapeutics Ltd |
In accordance with
Enquiries
BATM Advanced Communications |
|
Moti Nagar, Chief Executive Officer |
+972 9866 2525 |
Ran Noy, Chief Financial Officer |
|
|
|
Shore Capital |
|
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory) |
+44 20 7408 4050 |
|
|
Gracechurch Group |
|
Harry Chathli, Claire Norbury |
+44 20 4582 3500 |
Forward-looking statements
This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, due to the risk factors that are detailed in the Group's Annual Report, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.